Merck (MRK) CMD 2025 summary

Strategic Priorities and Portfolio Management

• Focused on growth, innovation, and sustainable value creation through disciplined portfolio management and capital allocation to high-return areas, both organically and inorganically.

• Active portfolio management includes recent acquisitions (SpringWorks Therapeutics, Myrus Bio, Unity SC, JSR's chromatography business) and divestments (Surface Solutions), prioritizing investments in attractive markets and divesting non-core assets.

• Over 80% of business operates in attractive markets with solid competitive positions; ongoing disciplined review ensures adaptability and resource optimization.

• Significant M&A capacity remains, especially in Life Science, with strict financial criteria and a holistic approach to resource allocation.

• Portfolio optimization is guided by market attractiveness, competitive position, and interdependencies.

Financial Guidance and Growth Outlook

• Targeting mid-single digit organic growth at group level over the midterm, with margin improvement of about 100 basis points and EBITDA pre margin around 29%.

• Life Science aims for mid to high single-digit organic CAGR, led by Process Solutions (~10% growth), with 2026 expected at mid-single digit before re-acceleration.

• Healthcare upgraded to low to mid-single digit organic growth midterm, with rare diseases as a new strategic pillar and launches of Ogsiveo, Gomekli, and Pimicotinib; 2026 expected at lower end due to timing of contributions and product cycles.

• Electronics expects mid to high single-digit organic sales growth, driven by semiconductor solutions and AI, with 2026 at lower end due to muted segments.

• Free cash flow to strengthen via improved operating cash flow, strong cash generation, and reduced CAPEX-to-sales ratio.

Business Segment Strategies and Drivers

• Life Science reorganized into three business units with tailored go-to-market strategies, digitalization, and customer-centricity to drive scalable growth and innovation.

• Process Solutions remains the main growth engine, targeting around 10% CAGR mid-term, supported by resilient manufacturing and regionalization.

• Healthcare's rare diseases business established through acquisitions, aiming for double-digit growth; Oncology and Neurology & Immunology managed for cash and sustainability.

• Electronics is now a pure-play advanced electronics sector, with 80% of business in semiconductor solutions and strong positioning in AI and advanced computing trends.

• Ongoing transformation in Life Science and Healthcare aims to simplify structures, empower teams, and reinvest in growth.